National
Destination Tomorrow works to empower LGBTQ community
Sean Coleman is Black transgender man who founded group in 2009
Sean Ebony Coleman became the first transgender African American to own and operate an LGBTQ center with the founding of Destination Tomorrow in 2009. Subsequent centers opened up in Atlanta in 2022 and D.C. in 2024.
Destination Tomorrow was founded on the idea that “it is more helpful to empower our most vulnerable TLGBQ+ community members in a way that takes them off the path of needing emergency care.”
“Our organization emphasizes economic, social, and mental empowerment through a variety of holistic educational, financial, support-based, housing, and health programs,” Destination Tomorrow said on the organization’s website.
With Transgender Day of Visibility today and WorldPride coming to D.C. this June, the Washington Blade spoke with Coleman to get some further insight into how Destination Tomorrow and other organizations are responding to the pressure the Trump-Vance administration is putting on the LGBTQ community.
BLADE: What was the overall reaction to the Trump administration and the heavy anti-LGBTQ rhetoric being pushed by the administration from Destination Tomorrow?
COLEMAN: I think the first thing was disbelief, right? You know he’s not well versed, but the embellishments about the community, particularly the trans community, were so outlandish that they became dangerous. So I think the first thing was, people actually believe this, and we have a message in problem because we’re not responding. We really missed an opportunity to message that differently. Like some of them it was so easy for us to respond and say, “We’re talking about the entire sports world when it comes to college and high school” and those kinds of things, right? We are definitely focusing on the wrong one percent.
I knew it was like collectively as a trans man, just personally, I was like “okay, so how do you show up now?” You’re in a position that folks expect you to at the very least have something positive to say next steps, this is what we’re gonna do, marching all this, whatever. I’m sitting with it like, no, I’m a little nervous. In the moment, most of the danger and most of the rhetoric is happening towards trans and gender nonconforming people and unfortunately, Black and brown and trans and gender nonconforming folks feel it worse when things like this happen.
BLADE: With a lot of organizations getting threats, losing funding, and everybody just being scared, has Destination Tomorrow specifically received any higher amounts of traffic to your locations, either here or other states?
COLEMAN: All three locations have seen an uptick. Funny thing a lot of them are coming in because they just want community. and we do that intake assessment. Then we say “while we have you here, we could do all of these other things.” But it’s really about them coming for community. If you know anything about us, we’re well versed in the house and ballroom community. So we put on balls. We’re planning one now.
And the young people, particularly young trans people, are also coming in for the ball, but they also want to know. Mr. Coleman, what can we do now? What is it? They want a call to action, want to be motivated and I think we have to figure out again this one message of where we’re going to go. Whether it is New York, Atlanta, and D.C., Destination Tomorrow is then going through all of the other trans into the nonconforming organizations. Speaking in one voice and figuring out what movement building looks like for us in this moment and we think that young people should drive it.
Particularly in New York and D.C. will receive some additional resources because we want to be able to address those folks that are going to come in. We want to make sure (to have enough) staff, (increase) our hours. We increase our security and our security presence because that was something that we were concerned about, even if it’s just an in person meeting that we’ve been doing for the last five years, because how do we keep those meetings and that meeting space and our identity safe?
BLADE: Do you feel like given the recent federal government layoffs and this whole Trump takeover of Washington, like, do you think D.C. is prepared or safe enough to start implementing those things that you want to try and get done?
COLEMAN: Yes. I think once we’ve taken a moment to step back and assess the situation, we will be able to come out stronger with the initiative that is going to be most important and most impactful for our community, but I think it is going to take some collaborative effort. I don’t think one agency is gonna be able to do it. I think this is a time for collaboration and allies. um, and not in that order. Right? But D.C. is definitely a safe place for LGBT community members worldwide.
It’s gonna be an amazing time. We’re gonna get an opportunity to show how resilient our community is, how much love we still receive. If you look at some things on social media, it’ll seem like everyone’s demonizing the trans and general nonconforming community and that’s not necessarily the case, right? I think we get sucked into this vacuum with social media and I think once you log off and you actually go outside, you recognize exactly how much support you have from your community. And I think that ties back into our messages. We’re not going to stand around sad and defeated. We’re going to show up, have a good time with WorldPride.
I also see it as an excellent opportunity to strategically put some plans in place. While we have you here, and we’re celebrating, we’re partying, but here is what our next steps will be. We have at least two or three next steps that collectively, you can go back down and all of us a picture goes saying two or three things. Say the same things, stay on message and I think World Pride will be an excellent opportunity to do so.
Along with the comments on TDOV and WorldPride, Coleman also spoke about the current state of LGBTQ politics.
“What’s so unfortunate for me is that we lean into our allies, right? Now is the time for our allies to take a look around the room and say “Oh wait. This person is missing [in the conversation], we should not be speaking on behalf of Black and brown people,” he told the Blade. “I specifically say Black and brown trans people. [Allies] shouldn’t be speaking on behalf of them because I know a few that can actually come here and speak on their own behalf and unfortunately it doesn’t happen. I think it’s because it’s tied into the losing funding across the board. So those LGB organizations are gonna feel that loss. And at some point they may feel like they have to step in and fill a void that they don’t necessarily have to because we’re here.”
Specifically in New York, Coleman has been looking toward the local government to help Destination Tomorrow and other organizations stay protected and operational during times like these.
“Trans, gender nonconforming and LGB issues go across different issues. Whether we’re talking about housing, criminal justice reform, or reproductive rights. We should be included in those discussions, and we should be included in those funding opportunities,” said Coleman. “And I think this gives us an opportunity to show that Destination Tomorrow has a program called Pride at Work. to the workforce development program, where we’re pitching it in D.C. and we’re actually in our third year of doing it in New York City. That’s an example of how workforce development should be for all of us, right?”
“So a lot of the work we’ve done in the last couple of months is really meeting with all our elected officials and saying, ‘This is the message that we’d like you to push. This is what we want to say, this is how we feel. Because you are not saying it, it feels like you left us behind. This is where you are missing the mark and it is up to you to fix it,’” he added.
A discussion for New York mayoral candidates took place later that evening. One of the things that Coleman wanted to heavily iterate to the candidates was that “at the end of the day, we’re paying attention now. We may not have been as politically engaged as we should have been, but we are now.”
A Wider Bridge on Friday announced it will shut down at the end of the month.
The group that “mobilizes the LGBTQ community to fight antisemitism and support Israel and its LGBTQ community” in a letter to supporters said financial challenges prompted the decision.
“After 15 years of building bridges between LGBTQ communities in North America and Israel, A Wider Bridge has made the difficult decision to wind down operations as of Dec. 31, 2025,” it reads.
“This decision comes after challenging financial realities despite our best efforts to secure sustainable funding. We deeply appreciate our supporters and partners who made this work possible.”
Arthur Slepian founded A Wider Bridge in 2010.
The organization in 2016 organized a reception at the National LGBTQ Task Force’s Creating Change Conference in Chicago that was to have featured to Israeli activists. More than 200 people who protested against A Wider Bridge forced the event’s cancellation.
A Wider Bridge in 2024 urged the Capital Pride Alliance and other Pride organizers to ensure Jewish people can safely participate in their events in response to an increase in antisemitic attacks after Hamas militants attacked Israel on Oct. 7, 2023.
The Jewish Telegraphic Agency reported authorities in Vermont late last year charged Ethan Felson, who was A Wider Bridge’s then-executive director, with lewd and lascivious conduct after alleged sexual misconduct against a museum employee. Rabbi Denise Eger succeeded Felson as A Wider Bridge’s interim executive director.
A Wider Bridge in June honored U.S. Rep. Debbie Wasserman Schultz (D-Fla.) at its Pride event that took place at the Capital Jewish Museum in D.C. The event took place 15 days after a gunman killed two Israeli Embassy employees — Yaron Lischinsky and Sarah Milgrim — as they were leaving an event at the museum.
“Though we are winding down, this is not a time to back down. We recognize the deep importance of our mission and work amid attacks on Jewish people and LGBTQ people – and LGBTQ Jews at the intersection,” said A Wider Bridge in its letter. “Our board members remain committed to showing up in their individual capacities to represent queer Jews across diverse spaces — and we know our partners and supporters will continue to do the same.”
Editor’s note: Washington Blade International News Editor Michael K. Lavers traveled to Israel and Palestine with A Wider Bridge in 2016.
The White House
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
President made announcement on Friday
President Donald Trump met with leaders from some of the world’s largest pharmaceutical companies at the White House on Friday to announce his new “Trump Rx” plan and outline efforts to reduce medication costs for Americans.
During the roughly 47-minute meeting in the Roosevelt Room, Trump detailed his administration’s efforts to cut prescription drug prices and make medications more affordable for U.S. patients.
“Starting next year, American drug prices will come down fast, furious, and will soon be among the lowest in the developed world,” Trump said during the meeting. “For decades, Americans have been forced to pay the highest prices in the world for prescription drugs by far … We will get the lowest price of anyone in the world.”
Trump signed an executive order in May directing his administration “to do everything in its power to slash prescription drug prices for Americans while getting other countries to pay more.”
“This represents the greatest victory for patient affordability in the history of American health care, by far, and every single American will benefit,” he added.
Several pharmaceutical executives stood behind the president during the announcement, including Sanofi CEO Paul Hudson, Novartis CEO Vas Narasimhan, Genentech CEO Ashley Magargee, Boehringer Ingelheim (USA) CEO Jean-Michel Boers, Gilead Sciences CEO Dan O’Day, Bristol Myers Squibb General Counsel Cari Gallman, GSK CEO Emma Walmsley, Merck CEO Robert Davis, and Amgen Executive Vice President Peter Griffith.
Also in attendance were Health and Human Services Secretary Robert F. Kennedy Jr., Commerce Secretary Howard Lutnick, Centers for Medicare and Medicaid Services Administrator Mehmet Oz, and Food and Drug Administration Commissioner Marty Makary.
Under the Trump Rx plan, the administration outlined a series of proposed drug price changes across multiple companies and therapeutic areas. Among them were reductions for Amgen’s cholesterol-lowering drug repatha from $573 to $239; Bristol Myers Squibb’s HIV medication reyataz from $1,449 to $217; Boehringer Ingelheim’s type 2 diabetes medication jentadueto from $525 to $55; Genentech’s flu medication xofluza from $168 to $50; and Gilead Sciences’ hepatitis C medication epclusa from $24,920 to $2,425.
Additional reductions included several GSK inhalers — such as the asthma inhaler advair diskus 500/50, from $265 to $89 — Merck’s diabetes medication januvia from $330 to $100, Novartis’ multiple sclerosis medication mayzent from $9,987 to $1,137, and Sanofi’s blood thinner plavix from $756 to $16. Sanofi insulin products would also be capped at $35 per month’s supply.
These prices, however, would only be available to patients who purchase medications directly through TrumpRx. According to the program’s website, TrumpRx “connects patients directly with the best prices, increasing transparency, and cutting out costly third-party markups.”
Kennedy spoke after Trump, thanking the president for efforts to lower pharmaceutical costs in the U.S., where evidence has shown that drug prices — including both brand-name and generic medications — are nearly 2.78 times higher than prices in comparable countries. According to the Pharmaceutical Research and Manufacturers of America, roughly half of every dollar spent on brand-name drugs goes to entities that play no role in their research, development, or manufacturing.
“This is affordability in action,” Kennedy said. “We are reversing that trend and making sure that Americans can afford to get the life-saving solutions.”
Gilead CEO Dan O’Day also spoke about how the restructuring of drug costs under TrumpRx, combined with emerging technologies, could help reduce HIV transmission — a virus that, if untreated, can progress to AIDS. The LGBTQ community remains disproportionately affected by HIV.
“Thank you, Mr. President — you and the administration,” O’Day said. “I think this objective of achieving the commitment to affordability and future innovation is extraordinary … We just recently launched a new medicine that’s only given twice a year to prevent HIV, and we’re working with Secretary Kennedy and his entire team, as well as the State Department, as a part of your strategy to support ending the epidemic during your term.
“I’ve never been more optimistic about the innovation that exists across these companies and the impact this could have on America’s health and economy,” he added.
Trump interjected, asking, “And that’s working well with HIV?”
“Yes,” O’Day replied.
“It’s a big event,” Trump said.
“It literally prevents HIV almost 100 percent given twice a year,” O’Day responded.
A similar anti-HIV medication is currently prescribed more than injectable form mentioned by O’Day. PrEP, is a medication regimen proven to significantly reduce HIV infection rates for people at high risk. Without insurance, brand-name Truvada can cost roughly $2,000 per month, while a generic version costs about $60 per month.
Even when medication prices are reduced, PrEP access carries additional costs, including clinic and laboratory fees, office visits, required HIV and sexually transmitted infection testing, adherence services and counseling, and outreach to potentially eligible patients and providers.
According to a 2022 study, the annual total cost per person for PrEP — including medication and required clinical and laboratory monitoring — is approximately $12,000 to $13,000 per year.
The TrumpRx federal platform website is now live at TrumpRx.gov, but the program is not slated to begin offering reduced drug prices until January.
The White House
EXCLUSIVE: Democracy Forward files FOIA lawsuit after HHS deadnames Rachel Levine
Trans former assistant health secretary’s name changed on official portrait
Democracy Forward, a national legal organization that works to advance democracy and social progress through litigation, policy and public education, and regulatory engagement, filed a lawsuit Friday in federal court seeking to compel the U.S. Department of Health and Human Services to release information related to the alteration of former Assistant Secretary for Health Adm. Rachel Levine’s official portrait caption.
The lawsuit comes in response to the slow pace of HHS’s handling of multiple Freedom of Information Act requests — requests that federal law requires agencies to respond to within 20 working days. While responses can take longer due to backlogs, high request volumes, or the need for extensive searches or consultations, Democracy Forward says HHS has failed to provide any substantive response.
Democracy Forward’s four unanswered FOIA requests, and the subsequent lawsuit against HHS, come days after someone in the Trump-Vance administration changed Levine’s official portrait in the Hubert H. Humphrey Building to display her deadname — the name she used before transitioning and has not used since 2011.
According to Democracy Forward, HHS “refused to release any records related to its morally wrong and offensive effort to alter former Assistant Secretary for Health Admiral Rachel Levine’s official portrait caption.” Levine was the highest-ranking openly transgender government official in U.S. history and served as assistant secretary for health and as an admiral in the U.S. Public Health Service Commissioned Corps from 2021 to 2025.
Democracy Forward President Skye Perryman spoke about the need to hold the Trump-Vance administration accountable for every official action, especially those that harm some of the most targeted Americans, including trans people.
“The question every American should be asking remains: what is the Trump-Vance administration hiding? For an administration that touts its anti-transgender animus and behavior so publicly, its stonewalling and silence when it comes to the people’s right to see public records about who was behind this decision is deafening,” Perryman said.
“The government’s obligation of transparency doesn’t disappear because the information sought relates to a trailblazing former federal official who is transgender. It’s not complicated — the public is entitled to know who is making decisions — especially decisions that seek to alter facts and reality, erase the identity of a person, and affect the nation’s commitment to civil rights and human dignity.”
“HHS’s refusal to respond to these lawful requests raises more serious concerns about transparency and accountability,” Perryman added. “The public has every right to demand answers — to know who is behind this hateful act — and we are going to court to get them.”
The lawsuit also raises questions about whether the alteration violated federal accuracy and privacy requirements governing Levine’s name, and whether the agency improperly classified the change as an “excepted activity” during a lapse in appropriations. By failing to make any determination or produce any records, Democracy Forward argues, HHS has violated its obligations under federal law.
The case, Democracy Forward Foundation v. U.S. Department of Health and Human Services, was filed in the U.S. District Court for the District of Columbia. The legal team includes Anisha Hindocha, Daniel McGrath, and Robin Thurston.
The Washington Blade reached out to HHS, but has not received any comment.
The lawsuit and four FOIA requests are below:
Long-awaited ‘Pillion’ surpasses the sexy buzz
Trump’s ‘American people derangement syndrome’
Reasons to be optimistic about 2026
Using movement to boost your mental health during holidays
Protecting the trans community is not optional for elected allies and candidates
Reasons to be optimistic about 2026
America is going in the wrong direction for intersex children
Rush reopens after renewing suspended liquor license
Long-awaited ‘Pillion’ surpasses the sexy buzz
